Lung cancer experts discuss the optimal management of CNS disease in EGFR-mutated non–small cell lung cancer.
|Videos|October 31, 2017
Dr. Garissino on Combinations With Immune Checkpoint Inhibitors in NSCLC
Author(s)Marina Chiara Garassino, MD
Marina Chiara Garassino, MD, medical consultant, Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, discusses combinations with immune checkpoint inhibitors in non-small cell lung cancer.
Advertisement
Marina Chiara Garassino, MD, medical consultant, Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, discusses combinations with immune checkpoint inhibitors in non—small cell lung cancer (NSCLC).
Garassino says that the future of immunotherapy in NSCLC lies in combinations.
In the future, treatment will be based on phenotype, says Garissino. The 3 phenotypes that are known right now in NSCLC are inflamed and immune-excluded, and immune-desert.
Advertisement
Related to this article
Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The phase 3 OptiTROP-Lung06 trial showed a PFS improvement with sac-TMT plus pembrolizumab in PD-L1–negative NSCLC.
The FDA has approved selpercatinib for RET fusion–positive advanced solid tumors.
Risvutatug rezetecan met the primary OS end point of the phase 3 ARTEMIS-008 trial in Chinese patients with relapsed small-cell lung cancer.
Phase 3 ELEVATE data show that adjuvant ensartinib significantly improved disease-free survival vs placebo in resected ALK-positive NSCLC.
A study from the Northwestern Medicine Canning Thoracic Institute indicates that lung transplant can extend survival in select advanced lung cancer cases.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL
4
Sonrotoclax and Next-Generation BCL-2 Inhibitors for Treating CLL
5